Morten A Karsdal1, Kim Henriksen2, Federica Genovese2, Diana J Leeming2, Mette J Nielsen2, Bente J Riis2, Claus Christiansen2,3, Inger Byrjalsen2, Detlef Schuppan4,5. 1. Nordic Bioscience A/S, Herlev Hovedgade 207, DK-2730, Herlev, Denmark. mk@nordicbioscience.com. 2. Nordic Bioscience A/S, Herlev Hovedgade 207, DK-2730, Herlev, Denmark. 3. Center for Clinical and Basic Research (CCBR), Ballerup, Denmark. 4. Institute of Translational Immunology and Research Center of Immune Therapy, University Medical Center, Johannes Gutenberg University, Mainz, Germany. 5. Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Abstract
AIMS/HYPOTHESIS: The treatment of type 2 diabetes with full peroxisome proliferator-activated receptor gamma (PPARγ) agonists improves insulin sensitivity, but is associated with weight gain, heart failure, peripheral oedema and bone loss. Endotrophin, the C-terminal fragment of the α3 chain of procollagen type VI (also called Pro-C6), is involved in both adipose tissue matrix remodelling and metabolic control. We established a serum assay for endotrophin to assess if this novel adipokine could identify type 2 diabetic patients who respond optimally to PPARγ agonists, improving the risk-to-benefit ratio. METHODS: The BALLET trial (NCT00515632) compared the glucose-lowering effects and safety of the partial PPARγ agonist balaglitazone with those of pioglitazone in individuals with type 2 diabetes on stable insulin therapy. The per protocol population (n = 297) was stratified into tertiles based on baseline endotrophin levels. Participants were followed-up after 26 weeks, after which correlational analysis was carried out between endotrophin levels and measures of glucose control. This is a secondary post hoc analysis. RESULTS: Endotrophin was significantly associated with therapeutic response to balaglitazone and pioglitazone. At week 26, only individuals in the upper two tertiles showed significant reductions in HbA1c and fasting serum glucose compared with baseline. The OR for a 1% and a 0.5% reduction in HbA1c for individuals in the upper two tertiles were 3.83 (95% CI 1.62, 9.04) p < 0.01, and 3.85 (95% CI 1.94, 7.61) p < 0.001, respectively. Endotrophin levels correlated with adipose tissue mass, insulin resistance and fatty liver index. Notably, PPARγ-associated adverse effects, such as moderate-to-severe lower extremity oedema, only occurred in the lower tertile. CONCLUSIONS/ INTERPRETATION: Elevated endotrophin serum levels predict response to two insulin sensitisers and reduce the risk of associated adverse effects, thereby, identifying patients with type 2 diabetes who may profit from PPARγ agonist treatment.
RCT Entities:
AIMS/HYPOTHESIS: The treatment of type 2 diabetes with full peroxisome proliferator-activated receptor gamma (PPARγ) agonists improves insulin sensitivity, but is associated with weight gain, heart failure, peripheral oedema and bone loss. Endotrophin, the C-terminal fragment of the α3 chain of procollagen type VI (also called Pro-C6), is involved in both adipose tissue matrix remodelling and metabolic control. We established a serum assay for endotrophin to assess if this novel adipokine could identify type 2 diabeticpatients who respond optimally to PPARγ agonists, improving the risk-to-benefit ratio. METHODS: The BALLET trial (NCT00515632) compared the glucose-lowering effects and safety of the partial PPARγ agonist balaglitazone with those of pioglitazone in individuals with type 2 diabetes on stable insulin therapy. The per protocol population (n = 297) was stratified into tertiles based on baseline endotrophin levels. Participants were followed-up after 26 weeks, after which correlational analysis was carried out between endotrophin levels and measures of glucose control. This is a secondary post hoc analysis. RESULTS: Endotrophin was significantly associated with therapeutic response to balaglitazone and pioglitazone. At week 26, only individuals in the upper two tertiles showed significant reductions in HbA1c and fasting serum glucose compared with baseline. The OR for a 1% and a 0.5% reduction in HbA1c for individuals in the upper two tertiles were 3.83 (95% CI 1.62, 9.04) p < 0.01, and 3.85 (95% CI 1.94, 7.61) p < 0.001, respectively. Endotrophin levels correlated with adipose tissue mass, insulin resistance and fatty liver index. Notably, PPARγ-associated adverse effects, such as moderate-to-severe lower extremity oedema, only occurred in the lower tertile. CONCLUSIONS/ INTERPRETATION: Elevated endotrophin serum levels predict response to two insulin sensitisers and reduce the risk of associated adverse effects, thereby, identifying patients with type 2 diabetes who may profit from PPARγ agonist treatment.
Entities:
Keywords:
Balaglitazone; Efficacy; PPARγ; Safety; Type 2 diabetes
Authors: Lauren N Bell; Jiangxia Wang; Sriya Muralidharan; Sadhana Chalasani; Allison M Fullenkamp; Laura A Wilson; Arun J Sanyal; Kris V Kowdley; Brent A Neuschwander-Tetri; Elizabeth M Brunt; Arthur J McCullough; Nathan M Bass; Anna Mae Diehl; Aynur Unalp-Arida; Naga Chalasani Journal: Hepatology Date: 2012-08-21 Impact factor: 17.425
Authors: Dariusz M Lebensztejn; Maria E Sobaniec-Łotowska; Michael Bauer; Maciej Kaczmarski; Michael Voelker; Detlef Schuppan Journal: Eur J Gastroenterol Hepatol Date: 2005-08 Impact factor: 2.566
Authors: M Shahin; D Schuppan; R Waldherr; J Risteli; L Risteli; E R Savolainen; C Oesterling; H M Abdel Rahman; A M el Sahly; S M Abdel Razek Journal: Hepatology Date: 1992-04 Impact factor: 17.425
Authors: M Alexandra Sorocéanu; Dengshun Miao; Xiu-Ying Bai; Hanyi Su; David Goltzman; Andrew C Karaplis Journal: J Endocrinol Date: 2004-10 Impact factor: 4.286
Authors: Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray Journal: Lancet Date: 2009-06-06 Impact factor: 79.321
Authors: Shu Sun; Kim Henriksen; Morten A Karsdal; Inger Byrjalsen; Jörn Rittweger; Gabriele Armbrecht; Daniel L Belavy; Dieter Felsenberg; Anders F Nedergaard Journal: PLoS One Date: 2015-12-07 Impact factor: 3.240
Authors: Diana Julie Leeming; Signe Holm Nielsen; Roslyn Vongsuvanh; Pruthviraj Uchila; Mette Juul Nielsen; Alexander L Reese-Petersen; David van der Poorten; Mohammed Eslam; Detlef Schuppan; Morten Asser Karsdal; Jacob George Journal: Hepat Oncol Date: 2020-12-18
Authors: Daniel Guldager Kring Rasmussen; Anthony Fenton; Mark Jesky; Charles Ferro; Peter Boor; Martin Tepel; Morten Asser Karsdal; Federica Genovese; Paul Cockwell Journal: Sci Rep Date: 2017-12-11 Impact factor: 4.379
Authors: Anthony Fenton; Mark D Jesky; Charles J Ferro; Jacob Sørensen; Morten A Karsdal; Paul Cockwell; Federica Genovese Journal: PLoS One Date: 2017-04-12 Impact factor: 3.240